다한증 치료 시장 : 종류별, 치료별, 연령별 - 세계 기회 분석과 산업 예측(2021-2031년)

The global hyperhidrosis treatment market was valued at $575.3 million in 2021, and is estimated to reach $ 950.7 million by 2031, growing at a CAGR of 5.1% from 2022 to 2031.

A person with hyperhidrosis experiences excessive and unpredictable sweating. When cool or when they are at rest, people with hyperhidrosis may nevertheless perspire. A person's body's sweat glands overreact in hyperhidrosis. Excessive sweating can occasionally be brought on by a health issue or emotion (such as anxiety). Controlling the symptoms of hyperhidrosis can be a constant struggle for many people. Hyperhidrosis patients seem to have excessively active sweat glands. Uncontrollable sweating can cause severe physical and emotional distress. The cause of hyperhidrosis is unidentified and it is generally believed to be the result of a disturbance with the portion of the nervous system that regulates sweating. The impact of hyperhidrosis symptoms on life can vary greatly in terms of their severity. 

The major factors that drive the growth of the hyperhidrosis treatment market are rise in incidence of hyperhidrosis and surge in product launch & product approval are the factors attributed to the growth of the hyperhidrosis treatment market. In addition, upsurge in utilization of topical treatments is a key trend of the market, which is expected to fuel the market growth during the forecast period.Significant surge in the incidence of hyperhidrosis is one leading factor for the growth of  the market. Estimates suggest between 2% and 5% of people in the U.S. have hyperhidrosis Thus, such high number of cases are expected to boost the hyperhidrosis treatment procedures.

In addition, rise in product launch drives the market growth, for instance, in June 2022, Dr August Wolff GmbH & Co. Kg Drugs presented the new drug Axhidrox. It is topical treatment for severe primary axillary hyperhidrosis in adults. However, lack of awareness about treatment scenario is expected to hinder the growth of the market. Conversely, increasing consumer demands in developing countries is expected to provide a great opportunity for the investors to invest in the market.

The hyperhidrosis treatment market is segmented on the basis of type, treatment, age, and region. On the basis of type, the market is categorized into axillary hyperhidrosis palmar hyperhidrosis, plantar hyperhidrosis, and others. By treatment, it is divided into botulinum toxin injection, topical treatment, and oral medication. Oral medication is further bifurcated into anticholinergics and others. By age, it is classified into below 50 years and above 50 years. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are AbbVie Inc, Avanor Healthcare Ltd  , Brickbell Biotech, Inc , Dr August Wolff GmbH & Co. Kg Drugs, Dr. Reddy's Laboratories Ltd, Eirion Therapeutics, Inc, Eli Lilly and Company, Hugel, Inc., Kaken Pharmaceutical Co., Ltd, Intas Pharmaceuticals Ltd, Roivant Sciences Ltd., and Theravida, Inc.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hyperhidrosis treatment market analysis from 2021 to 2031 to identify the prevailing hyperhidrosis treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the hyperhidrosis treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global hyperhidrosis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

• Axillary hyperhidrosis
• Palmar hyperhidrosis
• Plantar hyperhidrosis
• Others

By Treatment

• Botulinum toxin injections
• Topical treatment
• Oral medication
  • Type
  • Anticholinergics
  • Others

By Age

• Below 50 years
• Above 50 years

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest Of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest Of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest Of LAMEA
• Key Market Players
  • AbbVie Inc.
  • Avanor Healthcare Ltd
  • Brickbell Biotech, Inc
  • Dr August Wolff Gmbh & Co. Kg Drugs
  • Eirion Therapeutics, Inc
  • Eli Lilly and Company
  • Hugel, Inc
  • Kaken Pharmaceutical Co., Ltd.
  • Roivant Sciences Ltd.
  • Theravida, Inc
  • Dr. Reddy's Laboratories Ltd.
  • Intas Pharmaceuticals Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market
• 3.7.Patent Landscape

CHAPTER 4: HYPERHIDROSIS TREATMENT MARKET, BY TYPE

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Axillary hyperhidrosis
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
• 4.3 Palmar hyperhidrosis
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country
• 4.4 Plantar hyperhidrosis
  • 4.4.1 Key market trends, growth factors and opportunities
  • 4.4.2 Market size and forecast, by region
  • 4.4.3 Market analysis by country
• 4.5 Others
  • 4.5.1 Key market trends, growth factors and opportunities
  • 4.5.2 Market size and forecast, by region
  • 4.5.3 Market analysis by country

CHAPTER 5: HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Botulinum toxin injections
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
• 5.3 Topical treatment
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country
• 5.4 Oral medication
  • 5.4.1 Key market trends, growth factors and opportunities
  • 5.4.2 Market size and forecast, by region
  • 5.4.3 Market analysis by country
  • 5.4.4 Oral medication Hyperhidrosis Treatment Market by Type
    • 5.4.4.1 Anticholinergics Market size and forecast, by region
    • 5.4.4.2 Others Market size and forecast, by region

CHAPTER 6: HYPERHIDROSIS TREATMENT MARKET, BY AGE

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Below 50 years
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country
• 6.3 Above 50 years
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market analysis by country

CHAPTER 7: HYPERHIDROSIS TREATMENT MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Type
  • 7.2.3 North America Market size and forecast, by Treatment
    • 7.2.3.1 North America Oral medication Hyperhidrosis Treatment Market by Type
  • 7.2.4 North America Market size and forecast, by Age
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Market size and forecast, by Type
    • 7.2.5.1.2 Market size and forecast, by Treatment
    • 7.2.5.1.3 Market size and forecast, by Age
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Market size and forecast, by Type
    • 7.2.5.2.2 Market size and forecast, by Treatment
    • 7.2.5.2.3 Market size and forecast, by Age
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Market size and forecast, by Type
    • 7.2.5.3.2 Market size and forecast, by Treatment
    • 7.2.5.3.3 Market size and forecast, by Age
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Type
  • 7.3.3 Europe Market size and forecast, by Treatment
    • 7.3.3.1 Europe Oral medication Hyperhidrosis Treatment Market by Type
  • 7.3.4 Europe Market size and forecast, by Age
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Market size and forecast, by Type
    • 7.3.5.1.2 Market size and forecast, by Treatment
    • 7.3.5.1.3 Market size and forecast, by Age
    • 7.3.5.2 France
    • 7.3.5.2.1 Market size and forecast, by Type
    • 7.3.5.2.2 Market size and forecast, by Treatment
    • 7.3.5.2.3 Market size and forecast, by Age
    • 7.3.5.3 UK
    • 7.3.5.3.1 Market size and forecast, by Type
    • 7.3.5.3.2 Market size and forecast, by Treatment
    • 7.3.5.3.3 Market size and forecast, by Age
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Market size and forecast, by Type
    • 7.3.5.4.2 Market size and forecast, by Treatment
    • 7.3.5.4.3 Market size and forecast, by Age
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Market size and forecast, by Type
    • 7.3.5.5.2 Market size and forecast, by Treatment
    • 7.3.5.5.3 Market size and forecast, by Age
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Market size and forecast, by Type
    • 7.3.5.6.2 Market size and forecast, by Treatment
    • 7.3.5.6.3 Market size and forecast, by Age
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Type
  • 7.4.3 Asia-Pacific Market size and forecast, by Treatment
    • 7.4.3.1 Asia-Pacific Oral medication Hyperhidrosis Treatment Market by Type
  • 7.4.4 Asia-Pacific Market size and forecast, by Age
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Market size and forecast, by Type
    • 7.4.5.1.2 Market size and forecast, by Treatment
    • 7.4.5.1.3 Market size and forecast, by Age
    • 7.4.5.2 China
    • 7.4.5.2.1 Market size and forecast, by Type
    • 7.4.5.2.2 Market size and forecast, by Treatment
    • 7.4.5.2.3 Market size and forecast, by Age
    • 7.4.5.3 India
    • 7.4.5.3.1 Market size and forecast, by Type
    • 7.4.5.3.2 Market size and forecast, by Treatment
    • 7.4.5.3.3 Market size and forecast, by Age
    • 7.4.5.4 Australia
    • 7.4.5.4.1 Market size and forecast, by Type
    • 7.4.5.4.2 Market size and forecast, by Treatment
    • 7.4.5.4.3 Market size and forecast, by Age
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Market size and forecast, by Type
    • 7.4.5.5.2 Market size and forecast, by Treatment
    • 7.4.5.5.3 Market size and forecast, by Age
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Market size and forecast, by Type
    • 7.4.5.6.2 Market size and forecast, by Treatment
    • 7.4.5.6.3 Market size and forecast, by Age
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Type
  • 7.5.3 LAMEA Market size and forecast, by Treatment
    • 7.5.3.1 LAMEA Oral medication Hyperhidrosis Treatment Market by Type
  • 7.5.4 LAMEA Market size and forecast, by Age
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Market size and forecast, by Type
    • 7.5.5.1.2 Market size and forecast, by Treatment
    • 7.5.5.1.3 Market size and forecast, by Age
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Market size and forecast, by Type
    • 7.5.5.2.2 Market size and forecast, by Treatment
    • 7.5.5.2.3 Market size and forecast, by Age
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Market size and forecast, by Type
    • 7.5.5.3.2 Market size and forecast, by Treatment
    • 7.5.5.3.3 Market size and forecast, by Age
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Market size and forecast, by Type
    • 7.5.5.4.2 Market size and forecast, by Treatment
    • 7.5.5.4.3 Market size and forecast, by Age

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 AbbVie Inc.
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 Avanor Healthcare Ltd
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 Brickbell Biotech, Inc
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 Dr August Wolff Gmbh & Co. Kg Drugs
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 Eirion Therapeutics, Inc
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 Eli Lilly and Company
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 Hugel, Inc
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 Kaken Pharmaceutical Co., Ltd.
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 Roivant Sciences Ltd.
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 Theravida, Inc
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments
• 9.11 Dr. Reddy's Laboratories Ltd.
  • 9.11.1 Company overview
  • 9.11.2 Company snapshot
  • 9.11.3 Operating business segments
  • 9.11.4 Product portfolio
  • 9.11.5 Business performance
  • 9.11.6 Key strategic moves and developments
• 9.12 Intas Pharmaceuticals Ltd
  • 9.12.1 Company overview
  • 9.12.2 Company snapshot
  • 9.12.3 Operating business segments
  • 9.12.4 Product portfolio
  • 9.12.5 Business performance
  • 9.12.6 Key strategic moves and developments